Psyence Biomedical operates as a pre-revenue clinical-stage entity, where the absence of commercial sales necessitates a heavy reliance on external capital to fund its PEX010 development pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd.
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program
Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.
Benchmark PBM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Psyence Biomedical Ltd. (PBM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.96 | $4.39M | -0.24 | — | — | -58.62% | — | |
| $8.61 | $1.16B | -5.26 | — | — | -212.85% | — | |
| $8.96 | $555.38M | -2.56 | -9561.61% | — | -70.99% | — | |
| $105.02 | $14.39B | 337.47 | 2.72% | 5.53% | 4.89% | — | |
| $1.33 | $1.5M | -0.33 | — | -8269.53% | -81.74% | — | |
| $1.42 | $847.76K | -0.65 | — | — | -168.05% | — |
Psyence Biomedical Ltd. (PBM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PBM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Psyence Biomedical Ltd. (PBM) stock FAQ — growth, dividends, profitability & financials explained
No. Psyence Biomedical Ltd. (PBM) reported a net loss of $6.9M in fiscal year 2025.
Psyence Biomedical Ltd. (PBM) had a return on equity (ROE) of -58.6% in fiscal year 2025. A negative ROE means the company lost money over the period.
Psyence Biomedical Ltd. (PBM) had negative free cash flow of $8.6M in fiscal year 2025.
